Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
42 The FIGHT trial, which enrolled patients hospitalised for acute decompensated HFrEF, showed no improvement with liraglutide on the primary composite endpoint of death, HF rehospitalisation or change in N-terminal pro B-type natriuretic peptide levels
Toxicology Letters
Chatterjee, S., Prados-Rosales, R., Itin, B., Casadevall, A
Clients have the option of selecting from two different PA criteria a stricter version that aligns with the population in the clinical trial and another version based on the current labeled indication
US$ 23.96
US$ 24.34
US$ 28.25
